Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports

Anticancer Res. 2015 Aug;35(8):4545-9.

Abstract

Background: Gc protein-derived macrophage-activating factor (GcMAF) immunotherapy has been steadily advancing over the last two decades. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum has shown high macrophage phagocytic activity. GcMAF-based immunotherapy has a wide application for use in treating many diseases via macrophage activation or for use as supportive therapy.

Results: Three case studies demonstrate that oral colostrum MAF can be used for serious infection and chronic fatigue syndrome (CFS) without adverse effects.

Conclusion: We demonstrate that colostrum MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which is common in many chronic diseases.

Keywords: Immunotherapy; cancer; chronic fatigue syndrome (CFS); colostrum; macrophage-activating factor (MAF); myalgic encephalomyelitis (ME).

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Catastrophic Illness / therapy
  • Colostrum / immunology*
  • Fatigue Syndrome, Chronic / etiology
  • Fatigue Syndrome, Chronic / therapy*
  • Female
  • Fever / drug therapy
  • Humans
  • Immunotherapy / methods*
  • Infections / etiology
  • Infections / therapy*
  • Macrophage Activation / drug effects
  • Macrophage-Activating Factors / therapeutic use*
  • Macrophages / drug effects
  • Macrophages / immunology
  • Middle Aged
  • Neoplasms / complications*
  • Pregnancy
  • Vitamin D-Binding Protein / therapeutic use*

Substances

  • Macrophage-Activating Factors
  • Vitamin D-Binding Protein
  • vitamin D-binding protein-macrophage activating factor